The greater affinity of JC polyomavirus capsid for α2,6-linked lactoseries tetrasaccharide c than for other sialylated glycans is a major determinant of infectivity

Journal of Virology

Volumn 89, Issue 12, 2015, Pages 6364-6375

  Ströh, Luisa J ^a   Maginnis, Melissa S ^b,c   Blaum, Bärbel S ^a   Nelson, Christian D S ^b   Neu, Ursula ^a,f   Gee, Gretchen V ^b   O'Hara, Bethany A ^b   Motamedi, Nasim ^d   DiMaio, Daniel ^d   Atwood, Walter J ^b   Stehle, Thilo ^a,e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF MAINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CELL RECEPTOR; GANGLIOSIDE; GANGLIOSIDE GM3; GLYCAN; LACTOSERIES TETRASACCHARIDE C; PROTEIN MAD1; PROTEIN VP1; PROTEIN WT3; SIALIC ACID; TETRASACCHARIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN; GLYCAN SIALYLNEOLACTO-N-TETRAOSE C; POLYSACCHARIDE; SIALIC ACID DERIVATIVE; VIRUS RECEPTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EMBRYO; GENETIC VARIABILITY; GLIA CELL; HUMAN; HUMAN CELL; JC VIRUS; MOLECULAR CLONING; MOLECULAR RECOGNITION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RECEPTOR BINDING; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS PATHOGENESIS; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; METABOLISM; MOUSE; PHYSIOLOGY;

JC POLYOMAVIRUS; MIRIDAE;

ANIMALS; CAPSID PROTEINS; CRYSTALLOGRAPHY, X-RAY; HUMANS; JC VIRUS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; POLYSACCHARIDES; RECEPTORS, VIRUS; SIALIC ACIDS; VIRUS ATTACHMENT;

EID: 84929600851     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00489-15     Document Type: Article

References (68)

1. Kean JM, Rao S, Wang M, Garcea RL. 2009. Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363. http://dx.doi.org/10.1371/journal.ppat.1000363.
2. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH. 2009. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837-846. http://dx.doi.org/10.1086/597126.
3. Yogo Y, Kitamura T, Sugimoto C, Ueki T, Aso Y, Hara K, Taguchi F. 1990. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol 64:3139-3143.
4. Daniel AM, Swenson JJ, Mayreddy RP, Khalili K, Frisque RJ. 1996. Sequences within the early and late promoters of archetype JC virus restrict viral DNA replication and infectivity. Virology 216:90-101. http://dx.doi.org/10.1006/viro.1996.0037.
5. Dubois V, Dutronc H, Lafon ME, Poinsot V, Pellegrin JL, Ragnaud JM, Ferrer AM, Fleury HJ. 1997. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol 35:2288-2292.
6. Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P. 2011. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 204: 103-114. http://dx.doi.org/10.1093/infdis/jir198.
7. Silverman L, Rubinstein LJ. 1965. Electron microscopic observations on a case of progressive multifocal leukoencephalopathy. Acta Neuropathol 5:215-224. http://dx.doi.org/10.1007/BF00686519.
8. Zurhein G, Chou SM. 1965. Particles resembling papova viruses in human cerebral demyelinating disease. Science 148:1477-1479. http://dx.doi.org/10.1126/science.148.3676.1477.
9. Liedtke W, Edelmann W, Bieri PL, Chiu FC, Cowan NJ, Kucherlapati R, Raine CS. 1996. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 17:607-615. http://dx.doi.org/10.1016/S0896-6273(00)80194-4.
10. Spiegel I, Peles E. 2006. A new player in CNS myelination. Neuron 49:777-778. http://dx.doi.org/10.1016/j.neuron.2006.03.001.
11. Bradl M, Lassmann H. 2010. Oligodendrocytes: biology and pathology. Acta Neuropathol 119:37-53. http://dx.doi.org/10.1007/s00401-009-0601-5.
12. Astrom KE, Mancall EL, Richardson EP, Jr. 1958. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81:93-111. http://dx.doi.org/10.1093/brain/81.1.93.
13. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO. 2012. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471-506. http://dx.doi.org/10.1128/CMR.05031-11.
14. Kondo Y, Windrem MS, Zou L, Chandler-Militello D, Schanz SJ, Auvergne RM, Betstadt SJ, Harrington AR, Johnson M, Kazarov A, Gorelik L, Goldman SA. 2014. Human glial chimeric mice reveal astrocytic dependence of JC virus infection. J Clin Invest 124:5323-5336. http://dx.doi.org/10.1172/JCI76629.
15. Hirsch HH, Kardas P, Kranz D, Leboeuf C. 2013. The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 121:685-727. http://dx.doi.org/10.1111/apm.12128.
16. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. 2009. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816-824. http://dx.doi.org/10.1016/S1470-2045(09)70161-5.
17. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. 2012. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870-1880. http://dx.doi.org/10.1056/NEJMoa1107829.
18. Ermis U, Weis J, Schulz JB. 2013. Case reports of PML in patients treated for psoriasis. NEngl J Med 369:1081. http://dx.doi.org/10.1056/NEJMc1307680.
19. Ermis U, Weis J, Schulz JB. 2013. PML in a patient treated with fumaric acid. N Engl J Med 368:1657-1658. http://dx.doi.org/10.1056/NEJMc1211805.
20. Liddington RC, Yan Y, Moulai J, Sahli R, Benjamin TL, Harrison SC. 1991. Structure of simian virus 40 at 3.8-A resolution. Nature 354:278-284. http://dx.doi.org/10.1038/354278a0.
21. Chen XS, Stehle T, Harrison SC. 1998. Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. EMBO J 17:3233-3240. http://dx.doi.org/10.1093/emboj/17.12.3233.
22. Stehle T, Harrison SC. 1997. High-resolution structure of a polyomavirus VP1-oligosaccharide complex: implications for assembly and receptor binding. EMBO J 16:5139-5148. http://dx.doi.org/10.1093/emboj/16.16.5139.
23. Neu U, Woellner K, Gauglitz G, Stehle T. 2008. Structural basis of GM1 ganglioside recognition by simian virus 40. Proc Natl Acad Sci USA 105:5219-5224. http://dx.doi.org/10.1073/pnas.0710301105.
24. Neu U, Maginnis MS, Palma AS, Stroh LJ, Nelson CD, Feizi T, Atwood WJ, Stehle T. 2010. Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8:309-319. http://dx.doi.org/10.1016/j.chom.2010.09.004.
25. Neu U, Allen SA, Blaum BS, Liu Y, Frank M, Palma AS, Stroh LJ, Feizi T, Peters T, Atwood WJ, Stehle T. 2013. A structure-guided mutation in the major capsid protein retargets BK polyomavirus. PLoS Pathog 9:e1003688. http://dx.doi.org/10.1371/journal.ppat.1003688.
26. Neu U, Khan ZM, Schuch B, Palma AS, Liu Y, Pawlita M, Feizi T, Stehle T. 2013. Structures of B-lymphotropic polyomavirus VP1 in complex with oligosaccharide ligands. PLoS Pathog 9:e1003714. http://dx.doi.org/10.1371/journal.ppat.1003714.
27. Khan ZM, Liu Y, Neu U, Gilbert M, Ehlers B, Feizi T, Stehle T. 2014. Crystallographic and glycan microarray analysis of human polyomavirus 9 VP1 identifies N-glycolyl neuraminic acid as a receptor candidate. J Virol 88:6100-6111. http://dx.doi.org/10.1128/JVI.03455-13.
28. Assetta B, Maginnis MS, Gracia Ahufinger I, Haley SA, Gee GV, Nelson CD, O'Hara BA, Allen Ramdial SA, Atwood WJ. 2013. 5-Ht2 receptors facilitate Jc polyomavirus entry. J Virol 87:13490-13498. http://dx.doi.org/10.1128/JVI.02252-13.
29. Erickson KD, Garcea RL, Tsai B. 2009. Ganglioside GT1b is a putative host cell receptor for the Merkel cell polyomavirus. J Virol 83:10275-10279. http://dx.doi.org/10.1128/JVI.00949-09.
30. Qian M, Tsai B. 2010. Lipids and proteins act in opposing manners to regulate polyomavirus infection. J Virol 84:9840-9852. http://dx.doi.org/10.1128/JVI.01093-10.
31. Neu U, Stehle T, Atwood WJ. 2009. The Polyomaviridae: contributions of virus structure to our understanding of virus receptors and infectious entry. Virology 384:389-399. http://dx.doi.org/10.1016/j.virol.2008.12.021.
32. Maccioni HJ, Quiroga R, Ferrari ML. 2011. Cellular and molecular biology of glycosphingolipid glycosylation. J Neurochem 117:589-602. http://dx.doi.org/10.1111/j.1471-4159.2011.07232.x.
33. Cubitt CL, Cui X, Agostini HT, Nerurkar VR, Scheirich I, Yanagihara R, Ryschkewitsch CF, Stoner GL. 2001. Predicted amino acid sequences for 100 JCV strains. J Neurovirol 7:339-344. http://dx.doi.org/10.1080/13550280152537201.
34. Komagome R, Sawa H, Suzuki T, Suzuki Y, Tanaka S, Atwood WJ, Nagashima K. 2002. Oligosaccharides as receptors for JC virus. J Virol 76:12992-13000. http://dx.doi.org/10.1128/JVI.76.24.12992-13000.2002.
35. Maginnis MS, Stroh LJ, Gee GV, O'Hara BA, Derdowski A, Stehle T, Atwood WJ. 2013. Progressive multifocal leukoencephalopathyassociated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding. mBio 4(3):e00247-00213. http://dx.doi.org/10.1128/mBio.00247-13.
36. Sunyaev SR, Lugovskoy A, Simon K, Gorelik L. 2009. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 5:e1000368. http://dx.doi.org/10.1371/journal.pgen.1000368.
37. Major EO, Miller AE, Mourrain P, Traub RG, de Widt E, Sever J. 1985. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci USA 82:1257-1261. http://dx.doi.org/10.1073/pnas.82.4.1257.
38. Vacante DA, Traub R, Major EO. 1989. Extension of JC virus host range to monkey cells by insertion of a simian virus 40 enhancer into the JC virus regulatory region. Virology 170:353-361. http://dx.doi.org/10.1016/0042-6822(89)90425-X.
39. Nelson C, Carney D, Derdowski A, Lipovsky A, Gee G, O'Hara B, Williard P, DiMaio D, Sello J, Atwood W. 2013. A retrograde trafficking inhibitor of ricin and Shiga-like toxins inhibits infection of cells by human and monkey polyomaviruses. mBio 4(6):00729-13. http://dx.doi.org/10.1128/mBio.00729-13.
40. Chen BJ, Atwood WJ. 2002. Construction of a novel JCV/SV40 hybrid virus (JCSV) reveals a role for the JCV capsid in viral tropism. Virology 300:282-290. http://dx.doi.org/10.1006/viro.2002.1522.
41. Gee GV, Tsomaia N, Mierke DF, Atwood WJ. 2004. Modeling a sialic acid binding pocket in the external loops of JC virus VP1. J Biol Chem 279:49172-49176. http://dx.doi.org/10.1074/jbc.M409326200.
42. Maginnis MS, Haley SA, Gee GV, Atwood WJ. 2010. Role of N-linked glycosylation of the 5-HT2A receptor in JC virus infection. J Virol 84: 9677-9684. http://dx.doi.org/10.1128/JVI.00978-10.
43. Gee GV, O'Hara BA, Derdowski A, Atwood WJ. 2013. Pseudovirus mimics cell entry and trafficking of the human polyomavirus JCPyV. Virus Res 178:281-286. http://dx.doi.org/10.1016/j.virusres.2013.09.030.
44. Nelson CD, Derdowski A, Maginnis MS, O'Hara BA, Atwood WJ. 2012. The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry. Virology 428: 30-40. http://dx.doi.org/10.1016/j.virol.2012.03.014.
45. Kabsch W. 2010. Xds. Acta Crystallogr D Biol Crystallogr 66:125-132. http://dx.doi.org/10.1107/S0907444909047337.
46. McCoy AJ. 2007. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr D Biol Crystallogr 63:32-41. http://dx.doi.org/10.1107/S0907444906045975.
47. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235-242. http://dx.doi.org/10.1107/S0907444910045749.
48. Afonine PV, Grosse-Kunstleve RW, Adams PD. 2005. A robust bulk-solvent correction and anisotropic scaling procedure. Acta Crystallogr D Biol Crystallogr 61:850-855. http://dx.doi.org/10.1107/S0907444905007894.
49. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501. http://dx.doi.org/10.1107/S0907444910007493.
50. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255. http://dx.doi.org/10.1107/S0907444996012255.
51. Painter J, Merritt EA. 2006. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta CrystallogrDBiol Crystallogr 62:439-450. http://dx.doi.org/10.1107/S0907444906005270.
52. Howell PL, Smith GD. 1992. Identification of heavy-atom derivatives by normal probability methods. J Appl Crystallogr 25:81-86. http://dx.doi.org/10.1107/S0021889891010385.
53. Kleywegt GJ, Jones TA. 1996. xdlMAPMAN and xdlDATAMAN-programs for reformatting, analysis and manipulation of biomacromolecular electron-density maps and reflection data sets. Acta Crystallogr D Biol Crystallogr 52:826-828. http://dx.doi.org/10.1107/S0907444995014983.
54. Kleywegt GJ. 1999. Experimental assessment of differences between related protein crystal structures. Acta Crystallogr D Biol Crystallogr 55: 1878-1884. http://dx.doi.org/10.1107/S0907444999010495.
55. Burmeister WP, Guilligay D, Cusack S, Wadell G, Arnberg N. 2004. Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites. J Virol 78:7727-7736. http://dx.doi.org/10.1128/JVI.78.14.7727-7736.2004.
56. Stehle T, Harrison SC. 1996. Crystal structures of murine polyomavirus in complex with straight-chain and branched-chain sialyloligosaccharide receptor fragments. Structure 4:183-194. http://dx.doi.org/10.1016/S0969-2126(96)00021-4.
57. Tsai B, Gilbert JM, Stehle T, Lencer W, Benjamin TL, Rapoport TA. 2003. Gangliosides are receptors for murine polyoma virus and SV40. EMBO J 22:4346-4355. http://dx.doi.org/10.1093/emboj/cdg439.
58. Mayer M, Meyer B. 1999. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed Engl 38:1784-1788.
59. Magaldi TG, Buch MH, Murata H, Erickson KD, Neu U, Garcea RL, Peden K, Stehle T, DiMaio D. 2012. Mutations in the GM1 binding site of simian virus 40 VP1 alter receptor usage and cell tropism. J Virol 86: 7028-7042. http://dx.doi.org/10.1128/JVI.00371-12.
60. Szklarczyk OM, Gonzalez-Segredo N, Kukura P, Oppenheim A, Choquet D, Sandoghdar V, Helenius A, Sbalzarini IF, Ewers H. 2013. Receptor concentration and diffusivity control multivalent binding of Sv40 to membrane bilayers. PLoS Comput Biol 9:e1003310. http://dx.doi.org/10.1371/journal.pcbi.1003310.
61. Xiong X, Coombs PJ, Martin SR, Liu J, Xiao H, McCauley JW, Locher K, Walker PA, Collins PJ, Kawaoka Y, Skehel JJ, Gamblin SJ. 2013. Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature 497:392-396. http://dx.doi.org/10.1038/nature12144.
62. Anderson HA, Chen Y, Norkin LC. 1996. Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae. Mol Biol Cell 7:1825-1834. http://dx.doi.org/10.1091/mbc.7.11.1825.
63. Eash S, Querbes W, Atwood WJ. 2004. Infection of vero cells by BK virus is dependent on caveolae. J Virol 78:11583-11590. http://dx.doi.org/10.1128/JVI.78.21.11583-11590.2004.
64. Stroh LJ, Stehle T. 2014. Glycan Engagement by viruses: receptor switches and specificity. Annu Rev Virol 1:285-306. http://dx.doi.org/10.1146/annurev-virology-031413-085417.
65. Imai M, Kawaoka Y. 2012. The role of receptor binding specificity in interspecies transmission of influenza viruses. Curr Opin Virol 2:160-167. http://dx.doi.org/10.1016/j.coviro.2012.03.003.
66. Pastrana DV, Ray U, Magaldi TG, Schowalter RM, Cuburu N, Buck CB. 2013. BK polyomavirus genotypes represent distinct serotypes with distinct entry tropism. J Virol 87:10105-10113. http://dx.doi.org/10.1128/JVI.01189-13.
67. Agostini HT, Ryschkewitsch CF, Mory R, Singer EJ, Stoner GL. 1997. JC virus (JCV) genotypes in brain tissue from patients with progressive multifocal leukoencephalopathy (PML) and in urine from controls without PML: increased frequency of JCV type 2 in PML. J Infect Dis 176:1-8. http://dx.doi.org/10.1086/514010.
68. Demarco ML, Woods RJ, Prestegard JH, Tian F. 2010. Presentation of membrane-anchored glycosphingolipids determined from molecular dynamics simulations andNMRparamagnetic relaxation rate enhancement. J Am Chem Soc 132:1334-1338. http://dx.doi.org/10.1021/ja907518x.